Atropos Health Continues Commitment to Advancements in Oncology with Addition of Key Personnel
In addition to the growth of the Atropos Evidence Network, Atropos Health is also adding key personnel to enhance the oncology focus:
Cory D. Wiegert joins as Chief Operating Officer, bringing over 25 years of experience leading innovation and product development in enterprise software and healthcare IT including the launch of a cloud-based, AI-driven decision platform. His extensive background also includes overseeing the industry's largest dataset for value-based, specialty care at Integra Connect and leadership roles at CancerLinQ, IBM Watson Health, and Siebel Systems.
Dr. Morgan Cheatham joins the Atropos Health Board of Directors as a Board Observer bringing extensive expertise as Partner and Head of Healthcare and Life Sciences for Breyer Capital, where he leads investments across various sectors, including AI. Previously at Bessemer Venture Partners, he spearheaded early-stage investments in companies like Abridge and Hinge Health. Cheatham is also pursuing a fellowship in Clinical Genetics at Harvard/Boston Children's, serves on the Editorial Team for NEJM AI and Board Director for Coalition for Health AI, and has published research on clinical AI and genetic medicine in leading journals.
Jason Jones heads Data Science at Atropos Health bringing extensive experience as the former Chief Data Scientist at Health Catalyst and a Research Scientist and VP at Kaiser Permanente. His background also includes significant roles in medical informatics at Intermountain Healthcare and leadership positions at Bayer HealthCare and UnitedHealth Group.
"We're investing heavily in both product and personnel when it comes to applying RWE to oncology practice and research and development," said Dr. Brigham Hyde, CEO and co-founder at Atropos Health. "Bringing on additional Oncology-specific expertise signals our further investment and commitment to advancing life saving treatments in oncology. "
Along with the Ontada partnership, existing partner Norstella is now also an additional source of RWD for the Oncology MultiModal network in the Atropos Evidence Network, further enhancing the market leading federated oncology evidence network.
About Atropos Health
Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence.
To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
4 hours ago
- Bloomberg
Zimbabwe Bank Payments Disrupted by Outage That Hit Central Bank
Zimbabwean banks reported widespread disruption to a widely-used payment channel, after the central bank experienced a network problem that it is trying to fix. Lender's including the Central African Building Society Ltd., the nation's largest mortgage lender and a unit of South African insurer Old Mutual Ltd., advised clients Tuesday that the real-time gross settlement platform was down.
Business Wire
5 hours ago
- Business Wire
Daversa Earns Great Place To Work Certification™ for Fourth Consecutive Year
NEW YORK--(BUSINESS WIRE)--Daversa is proud to announce its fourth consecutive Great Place To Work® Certification™. With 98% of employees affirming that Daversa is a great place to work - far above the 57% average for U.S. companies - this recognition underscores our commitment to building an exceptional culture. 'This recognition is about the people who make Daversa what it is,' said Founder and CEO, Paul Daversa. 'While the industry transforms monthly through the power of AI, we remain the one firm consistently training the tech industry's most elite recruiters. At Daversa, culture and being a Great Place to Work revolve around obsessing over the experiences we deliver to our people in the office, so they can deliver outsized results for our clients. You can't obsess over clients if you don't first obsess over your people, and having our employees recognize that is something I'm incredibly proud of.' About Daversa Daversa is technology's premier executive search firm that builds the leadership teams for growth and venture-backed companies. Our global footprint spans two continents and eight offices, giving our high-performance teams visibility into the entirety of the market. We are dedicated to developing meaningful relationships with entrepreneurs, executives, and investors across consumer and enterprise businesses. Extraordinary talent is hard to find and even harder to recruit. Focusing our searches on delivering Material Impact executives is what sets us apart, and is what makes Daversa the search partner of choice. About Great Place to Work Certification™ Great Place To Work® Certification™ is the most definitive 'employer-of-choice' recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place To Work-Certified. About Great Place To Work ® As the global authority on workplace culture, Great Place To Work® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified™ or receiving recognition on a coveted Best Workplaces™ List.
Business Wire
6 hours ago
- Business Wire
Pleural Dynamics Announces Completion of Enrollment of 'The ACES Study for Aseptic Pleural Effusions,' a Post Market Study Evaluating the Novel ACES Automatic Continuous Effusion Shunt System
MINNEAPOLIS--(BUSINESS WIRE)--Pleural Dynamics, a medical device company that is building solutions for recurrent fluid collections in the body, announced today that the final patient in 'The ACES™ Study for Aseptic Pleural Effusions' post-market clinical study has been enrolled at Memorial Regional Hospital in Hollywood, Florida. The company's ACES™ Automatic Continuous Effusion Shunt System is the first and only fully implantable automatic effusion shunt that uses the motion of normal breathing to remove fluid from the chest. It is designed for continuous symptom relief and does not require an extended hospital stay, a catheter external to the chest, or expensive drainage canisters. 'Hearing stories from patients who've experienced decreased shortness of breath and renewed ease in daily activities reinforces our mission to bring forward innovations that improve lives.' - Martin Mayse, Founder and CEO of Pleural Dynamics. The current standards of care for recurrent pleural effusion (PE) have several significant shortcomings for patients. One standard approach for treating recurrent PE's is pleurodesis, which is painful, requires an extended hospital stay, and is often unsuccessful requiring additional procedures (1). A common alternate approach—indwelling pleural catheters—requires a portion of the catheter to be external to the chest and needs frequent drainage into expensive external canisters to relieve symptoms. Pleural Dynamics' patented ACES™ System addresses these shortcomings (2) with its one-piece, fully implanted system that is placed with a minimally invasive procedure during a short hospital stay. The device uses normal breathing motion to automatically pump pleural effusion fluid from the chest into the abdomen for reabsorption by the body, eliminating the need for an external catheter and frequent drainage. It is designed to relieve the shortness of breath associated with PE's and improve the quality of life for patients. 'We're thrilled to have participated in this study of the ACES device for patients suffering from recurrent pleural effusion, and to have been the center to enroll the last patient and bring this study to a close,' said Mark Block, M.D., Chief of Thoracic Surgery at Memorial Healthcare System. 'This marks a major step toward understanding how this device can improve not only clinical outcomes but also the day-to-day quality of life for these patients struggling with other comorbidities like cancer. We look forward to seeing the data and are excited by the potential ACES holds for transforming care for this often-overlooked condition.' In this prospective, multi-center, single-arm study, 25 patients experiencing recurrent symptomatic pleural effusions at four U.S. centers received the ACES device. All study patients are being monitored for changes in their pleural effusion volume to demonstrate ACES System function. Other assessments evaluate shortness of breath, quality of life, and healthcare utilization to demonstrate the impact on patients' health and well-being. Study results will be summarized and submitted for publication later this year. 'Completing enrollment in this study is a proud milestone for our team,' said Martin Mayse, Founder and CEO of Pleural Dynamics. 'We're eagerly anticipating the outcomes data, which we believe will validate what patients and clinicians have already begun to tell us — that this device is making a meaningful difference in their quality of life. Hearing stories from patients who've experienced decreased shortness of breath and renewed ease in daily activities reinforces our mission to bring forward innovations that improve lives.' The ACES System received FDA 510(k) clearance in August 2023, and the results of this study will support the market release of the device in the United States later this year. About Pleural Dynamics Pleural Dynamics is a Minnesota-based medical device company, founded in 2020 by pulmonologist Dr. Martin Mayse and medtech veteran John Streeter. Frustrated with the current costly, cumbersome, and decades-old technologies to treat debilitating pleural diseases, Pleural Dynamics seeks to revolutionize care by bringing effective treatment options to patients and providers that reduce the overall cost of care through reductions in hospital stays, decreased caretaker labor and reduced infection rates. For more information, visit and connect on LinkedIn at References 1 Thomas R, Fysh ETH, Smith NA, Lee P, Kwan BCH, Yap E, Horwood FC, Piccolo F, Lam DCL, Garske LA, Shrestha R, Kosky C, Read CA, Murray K, Lee YCG. Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial. JAMA. 2017 Nov 21;318(19):1903-1912. 2 Heffner MD, John E. Management of Malignant Pleural Effusions. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. (Accessed on June 18, 2024)
